FEP Benefits Changes for Infliximab Effective Jan. 1, 2019.

November 9, 2018

The autoimmune drug infliximab will be covered as a medical benefit for Blue Cross and Blue Shield Federal Employee Program® (FEP) members who receive their first infusion on or after Jan. 1, 2019. Prior to 1/1/19, FEP members may be receiving infliximab under either pharmacy or medical benefits. Members currently receiving infliximab under pharmacy benefits will continue to receive it under pharmacy benefits after Jan. 1, 2019. FEP will notify these members.  There is no change for members who are currently receiving infliximab under their medical benefits.

If a member was receiving infliximab prior to Jan. 1, 2019 and they change FEP benefit plans or health insurers, they will receive the drug under their medical benefits regardless of how they previously received it.

Infliximab brand names are Remicade, Inflectra and Renflexis. It is an intravenous antibody that is used to treat many life-long inflammatory health problems.

Third-party brand names are the property of their respective owner.